The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial ...

Researchers from ETH Zurich have developed a new generative artificial intelligence (AI)-based computer process to develop drug molecules based on a protein’s three-dimensional surface. The new ...

Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

Foundation’s test to be used in Oxford-led blood biomarker trial The Food for the Brain Foundation’s Cognitive Function Test is set to play a central role in the UK-based ‘READ OUT’ trial, which is ...